EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell resistance to current immunotherapies, has signed a collaboration and ...

Argus upgraded AbbVie (ABBV) to Buy from Hold with a $220 price target Two of the company’s key immunology products, Skyrizi and Rinvoq, have succeeded Humira as growth engines, with the former having ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...

Biotherapeutic firm EvolveImmune Therapeutics gets $65 million upfront and potentially $1.4 billion more if drugmaker AbbVie licenses its T-cell therapy.

AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...

AbbVie (ABBV) and EvolveImmune Therapeutics announced a collaboration and option-to-license agreement to develop multispecific ...

AbbVie has inked a deal to work with privately held immuno-oncology company EvolveImmune Therapeutics, to develop therapeutic antibodies for cancer.

Woodward, Inc. (NASDAQ: WWD), a leader in aerospace and industrial energy control solutions, announced today that it expects to report its fiscal 2024 fourth quarter and full year financial results at ...